President Donald Trump’s announcement that his administration will impose a 100 percent tariff on patented pharmaceutical products sparked confusion Friday, as government officials, drug companies and trade groups sought clarity on how the levy would be applied. But the plan delivered one unambiguous mandate: It sent drugmakers scurrying to show that they are building manufacturing capacity in the United States.

See Full Page